X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (906) 906
Publication (70) 70
Book Review (4) 4
Magazine Article (4) 4
Government Document (2) 2
Book / eBook (1) 1
Book Chapter (1) 1
Newsletter (1) 1
Technical Report (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (621) 621
aniline compounds - adverse effects (406) 406
male (397) 397
female (332) 332
index medicus (319) 319
animals (291) 291
adult (208) 208
middle aged (195) 195
aniline compounds - therapeutic use (183) 183
aged (137) 137
aniline compounds - pharmacology (135) 135
rats (134) 134
aniline compounds - administration & dosage (111) 111
mice (108) 108
aniline (83) 83
aniline compounds - toxicity (81) 81
oncology (77) 77
aniline compounds - chemistry (76) 76
toxicology (74) 74
pharmacology & pharmacy (71) 71
aniline compounds (66) 66
dose-response relationship, drug (61) 61
aniline compounds - pharmacokinetics (57) 57
environmental sciences (57) 57
time factors (57) 57
coloring agents - adverse effects (56) 56
nitriles - adverse effects (53) 53
quinolines - adverse effects (53) 53
adolescent (51) 51
antineoplastic agents - adverse effects (51) 51
clinical trials as topic (50) 50
antineoplastic agents - therapeutic use (48) 48
aged, 80 and over (46) 46
analysis (46) 46
protein kinase inhibitors - adverse effects (44) 44
administration, oral (43) 43
aniline compounds - metabolism (43) 43
toxicity (43) 43
cancer (41) 41
nitriles - therapeutic use (39) 39
quinolines - therapeutic use (39) 39
research (39) 39
treatment outcome (39) 39
protein kinase inhibitors - therapeutic use (37) 37
article (36) 36
rats, sprague-dawley (34) 34
bosutinib (33) 33
in-vitro (33) 33
leukemia, myelogenous, chronic, bcr-abl positive - drug therapy (33) 33
occupational diseases - chemically induced (33) 33
public, environmental & occupational health (33) 33
apoptosis (32) 32
carcinogens (32) 32
occupational exposure - adverse effects (32) 32
dasatinib (31) 31
expression (30) 30
young adult (30) 30
aniline compounds - analysis (29) 29
care and treatment (28) 28
chemical industry (27) 27
disease models, animal (27) 27
health aspects (27) 27
hematology (27) 27
pyrimidines - adverse effects (27) 27
imidazoles - adverse effects (26) 26
pregnancy (26) 26
research article (26) 26
urinary bladder neoplasms - chemically induced (26) 26
alzheimer disease - diagnostic imaging (25) 25
antineoplastic agents - pharmacology (25) 25
apoptosis - drug effects (25) 25
imatinib mesylate (25) 25
pharmacokinetics (25) 25
pyrimidines - therapeutic use (25) 25
aniline compounds - poisoning (24) 24
child (24) 24
dermatitis, allergic contact - etiology (24) 24
leukemia (24) 24
liver - drug effects (24) 24
neoplasms - drug therapy (24) 24
patch tests (24) 24
risk factors (24) 24
sulfonamides - adverse effects (24) 24
calcium - metabolism (23) 23
cells, cultured (23) 23
chronic myelogenous leukemia (23) 23
dermatitis, contact - etiology (23) 23
exposure (23) 23
metabolism (23) 23
mutation (23) 23
safety (23) 23
therapy (23) 23
allergy (22) 22
alzheimer's disease (22) 22
antineoplastic agents - administration & dosage (22) 22
neurosciences (22) 22
nitriles - administration & dosage (22) 22
chemistry (21) 21
drug therapy (21) 21
medicine (21) 21
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (765) 765
German (48) 48
Russian (30) 30
French (20) 20
Italian (13) 13
Chinese (10) 10
Japanese (10) 10
Polish (6) 6
Spanish (4) 4
Portuguese (2) 2
Romanian (2) 2
Swedish (2) 2
Bulgarian (1) 1
Czech (1) 1
Dutch (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 04/2015, Volume 372, Issue 18, pp. 1689 - 1699
AZD9291, an irreversible inhibitor of epidermal growth factor receptor, was associated with tumor responses in the majority of patients with advanced... 
MEDICINE, GENERAL & INTERNAL | GEFITINIB | PLACEBO | PHASE-III | ACQUIRED-RESISTANCE | OPEN-LABEL | MUTATIONS | AFATINIB | IRREVERSIBLE EGFR | CHEMOTHERAPY | ERLOTINIB | Lung Neoplasms - drug therapy | Humans | Middle Aged | ErbB Receptors - genetics | Male | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Acrylamides - pharmacokinetics | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Aniline Compounds - administration & dosage | Lung Neoplasms - genetics | Protein Kinase Inhibitors - pharmacokinetics | ErbB Receptors - antagonists & inhibitors | Carcinoma, Non-Small-Cell Lung - genetics | Aniline Compounds - pharmacokinetics | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Drug Resistance, Neoplasm - genetics | Acrylamides - administration & dosage | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Mutation | Aniline Compounds - adverse effects | Acrylamides - adverse effects | Clinical trials | Care and treatment | Usage | Diagnosis | Lung cancer, Non-small cell | Patient outcomes | Tyrosine | Appetite | Inhibitor drugs | Epidermal growth factor receptors | Lung cancer | Diarrhea | Nausea | Drug resistance | Kinases | Patients | Epidermal growth factor | Pharmacokinetics | Protein-tyrosine kinase | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2010, Volume 11, Issue 12, pp. 1149 - 1159
Journal Article
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2012, Volume 30, Issue 5, pp. 488 - 496
Purpose BCL2 overexpression is a hallmark of chronic lymphocytic leukemia (CLL). The novel BH3 mimetic navitoclax (ABT-263) specifically inhibits BCL2 and... 
APOPTOSIS | LYMPHOMA-CELLS | ANTAGONIST ABT-737 | ONCOLOGY | SENSITIVITY | RESISTANCE | BH3 MIMETIC ABT-737 | CANCER | CHEMOTHERAPY | CELL-DEATH | FAMILY | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Male | Antineoplastic Agents - administration & dosage | Leukemia, Lymphocytic, Chronic, B-Cell - genetics | Proto-Oncogene Proteins c-bcl-2 - metabolism | Bcl-2-Like Protein 11 | Antineoplastic Agents - adverse effects | Biomarkers, Tumor - metabolism | Female | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Membrane Proteins - metabolism | Aniline Compounds - administration & dosage | Chromosome Deletion | Proto-Oncogene Proteins - metabolism | Aniline Compounds - pharmacology | Drug Administration Schedule | Administration, Oral | In Situ Hybridization, Fluorescence | Treatment Outcome | Thrombocytopenia - chemically induced | Aniline Compounds - pharmacokinetics | Sulfonamides - pharmacology | Sulfonamides - pharmacokinetics | Apoptosis Regulatory Proteins - metabolism | Leukemia, Lymphocytic, Chronic, B-Cell - metabolism | Myeloid Cell Leukemia Sequence 1 Protein | Sulfonamides - adverse effects | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Aged | Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy | Aniline Compounds - adverse effects | Sulfonamides - administration & dosage | Hema7 | ORIGINAL REPORTS
Journal Article
Journal of the American Society of Nephrology, ISSN 1046-6673, 09/2017, Volume 28, Issue 9, pp. 2756 - 2767
Journal Article
Cancer Research, ISSN 0008-5472, 05/2008, Volume 68, Issue 9, pp. 3421 - 3428
Overexpression of the prosurvival Bcl-2 family members (Bcl-2, Bcl-xL, and McI-1) is commonly associated with tumor maintenance, progression, and... 
MULTIPLE-MYELOMA | ONCOLOGY | INDUCED APOPTOSIS | CELL LYMPHOMA | X-L | MCL-1 | NON-HODGKINS-LYMPHOMA | BH3 MIMETIC ABT-737 | PROTEINS | UP-REGULATION | CANCER | Lung Neoplasms - drug therapy | Humans | Lymphoma, Mantle-Cell - pathology | Lung Neoplasms - pathology | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Antineoplastic Agents - adverse effects | Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology | Aniline Compounds - administration & dosage | Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications | Antibodies, Monoclonal, Murine-Derived | Administration, Oral | Carcinoma, Small Cell - drug therapy | Cells, Cultured | Lymphoma, Mantle-Cell - drug therapy | Rituximab | Treatment Outcome | Thrombocytopenia - chemically induced | Tumor Burden | Mice, SCID | Mice, Knockout | Neoplasms - drug therapy | Drug Synergism | Xenograft Model Antitumor Assays | Animals | Sulfonamides - therapeutic use | Antibodies, Monoclonal - administration & dosage | Models, Biological | Sulfonamides - adverse effects | Proto-Oncogene Proteins c-bcl-2 - antagonists & inhibitors | Mice | Aniline Compounds - therapeutic use | Aniline Compounds - adverse effects | Carcinoma, Small Cell - pathology | Neoplasms - pathology | Sulfonamides - administration & dosage | Index Medicus
Journal Article
The Oncologist, ISSN 1083-7159, 05/2011, Volume 16, Issue 5, pp. 566 - 578
Src is believed to play an important role in cancer, and several agents targeting Src are in clinical development. Design. We reviewed Src structure and... 
Dasatinib | Solid tumor | Biologic | Bosutinib | Src inhibitors | Saracatinib | SARACATINIB AZD0530 | ACTIVATION | PROTEIN-TYROSINE KINASES | PHASE-II | CELL-CYCLE ARREST | DASATINIB BMS-354825 | GROWTH-FACTOR RECEPTOR | COLON-CANCER CELLS | ONCOLOGY | PROSTATE-CANCER | C-SRC | Humans | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Thiazoles - therapeutic use | Pyrimidines - chemistry | Thiazoles - adverse effects | Dose-Response Relationship, Drug | Protein Kinase Inhibitors - chemistry | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Benzodioxoles - adverse effects | Benzodioxoles - chemistry | Benzodioxoles - therapeutic use | Quinazolines - chemistry | Quinolines - chemistry | src-Family Kinases - antagonists & inhibitors | Antineoplastic Combined Chemotherapy Protocols | Clinical Trials as Topic | Antineoplastic Agents - chemistry | Neoplasms - drug therapy | Protein Kinase Inhibitors - therapeutic use | Pyrimidines - therapeutic use | Quinazolines - therapeutic use | Nitriles - chemistry | Pyrimidines - adverse effects | Quinazolines - adverse effects | Thiazoles - chemistry | Quinolines - therapeutic use | Aniline Compounds - chemistry | Aniline Compounds - therapeutic use | Aniline Compounds - adverse effects | Nitriles - adverse effects | src-Family Kinases - chemistry | src-Family Kinases - genetics | Quinolines - adverse effects | Nitriles - therapeutic use | Cancer Biology
Journal Article